Resolvin E1对小鼠肺动脉高压的作用及机制研究
批准号:
81900046
项目类别:
青年科学基金项目
资助金额:
21.0 万元
负责人:
刘贵珠
依托单位:
学科分类:
肺循环与肺血管疾病
结题年份:
2022
批准年份:
2019
项目状态:
已结题
项目参与者:
关键词:
中文摘要
肺动脉平滑肌细胞(PASMCs)过度增殖导致的血管重塑,是肺动脉高压(PH)重要的病理特征。炎性介质Resolvin E1 (RvE1)可以作用于炎性细胞,促进炎症消退;也可以调控非炎性细胞(如平滑肌细胞)的功能,目前RvE1在PH中的作用仍不清楚。我们前期实验发现:RvE1可以显著改善小鼠低氧诱导的PH,降低PASMCs的增殖水平,提高Hippo信号通路中关键效应蛋白YAP的磷酸化。因此我们推测:RvE1可能通过Hippo-YAP信号通路影响小鼠低氧诱导的PH。为了验证这一假设,本研究构建ChemR23F/FSM22αCre和BLT1F/FSM22αCre小鼠,揭示RvE1发挥对小鼠低氧诱导PH保护作用所通过的受体;探究RvE1是否通过Hippo信号通路降低PASMCs增殖水平;探究RvE1促进YAP磷酸化所通过的蛋白激酶;探究下游和YAP结合的转录因子。该研究为PH的治疗提供新的靶点。
英文摘要
Pulmonary hypertension (PH) is characterized by excessive proliferation in pulmonary vascular smooth muscle, which caused pulmonary vascular remodeling. Resolvin E1, which generates from omega-3 polyunsaturated fatty acids (PUFAs), plays a wide range role of anti-inflammatory effects through acting directly on inflammatory cells. It can also acts on non-inflammatory cells, such as smooth muscle cell, affecting its proliferation and migration processes. The exact role of RvE1 in PH remains unclear. Our previous studies have found that: RvE1 can protect against hypoxic-induced pulmonary hypertension by reducing the proliferation level of pulmonary artery smooth muscle cells through increase phosphorylation of yes-associated protein 1 (YAP). We hypothesize that: RvE1 may ameliorate hypoxic-induced PH in mice through Hippo-YAP signaling pathway. In order to verify this hypothesis, we plan to use ChemR23F/FSM22αCre and BLT1F/FSM22αCre mice, to reveal the receptor mediated by RvE1 in the protective effect on hypoxia-induced PH in mice; to explore whether RvE1 reduces PASMCs proliferation through Hippo signaling pathways; to investigate the protein kinase which promotes YAP phosphorylation; to explore the downstream transcription factor that bind to YAP. These results provide, to our knowledge, the first empirical evidence that RvE1-ChemR23 signaling axis as a novel target for treating PH.
肺动脉高压(PH)是一种以严重的肺血管壁重塑和血管周围炎症为特征的毁灭性疾病。Resolvin E1 (RvE1)是一种促进炎症消解的脂质介质,对多种炎症性疾病具有保护作用。本课题通过对低氧+SU5416(HySu)诱导的小鼠PH模型和野百合碱诱导的大鼠PH模型以及从PH患者中收集肺组织和血浆样本,检测发现:特发性PH患者的血浆和PH实验啮齿动物模型的肺中,RvE1的生成减少;在缺氧暴露的小鼠肺动脉平滑肌细胞(PASMCs)、PH啮齿动物和特发性PH患者的肺动脉中,ChemR23的表达明显下调。进而通过多种分子生物学和组学手段,发现RvE1可以降低PH进程中肺血管周围炎性细胞的浸润水平降低炎症反应;同时降低PASMCs的增殖水平从而延缓PH的进程;血管平滑肌细胞中ChemR23的缺失消除了RvE1对HySU诱导的小鼠PH的保护作用。在机制上,RvE1/ChemR23轴通过抑制增殖性Wnt7a/β-catenin信号通路抑制缺氧诱导的PASMC增殖。RvE1激活ChemR23通过抑制PKA介导的Egr2 Ser349位点磷酸化降低PASMCs中Wnt7a的表达。因此,RvE1/ChemR23轴通过调节PASMCs中的Wnt7a/β-catenin信号通路抑制PH进程,并有望作为PH治疗的新靶点。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Resolvin E1 Attenuates Pulmonary Hypertension by Suppressing Wnt7a/β-Catenin Signaling
Resolvin E1 通过抑制 Wnt7a/β-连环蛋白信号传导减轻肺动脉高压
DOI:
10.1161/hypertensionaha.121.17809
发表时间:
2021-12-01
期刊:
HYPERTENSION
影响因子:
8.3
作者:
[Liu, Guizhu, Wan, Naifu, Wang, Jian]
通讯作者:
Wang, Jian
ResolvinE1-ChemR23-YAP信号通路在低氧诱导的小鼠肺动脉高压中的作用及机制研究
-
批准号:--
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:刘贵珠
-
依托单位:
国内基金
海外基金